Literature DB >> 11939811

Improved differentiation of benign and malignant lymphadenopathy in patients with cutaneous melanoma by contrast-enhanced color Doppler sonography.

Monika-Hildegard Schmid-Wendtner1, Karin Partscht, Hans Christian Korting, Matthias Volkenandt.   

Abstract

OBJECTIVE: To evaluate whether administration of a D-galactose-based signal enhancer is useful in color Doppler sonography (CDS) for better detection of vascularity patterns, which may help to differentiate malignant from benign lymph nodes in patients with cutaneous melanomas.
DESIGN: Comparison of B-mode sonography, native CDS, and signal-enhanced CDS.
SETTING: Department of Dermatology and Allergology, Ludwig-Maximilians-University, Munich, Germany. PATIENTS: Twenty examinations in 19 patients (median age, 60 years; 10 men) who presented with echo-poor structures suggestive of lymphadenopathy in B-mode sonography during follow-up for cutaneous melanomas.
INTERVENTIONS: Histopathologic and follow-up examinations; documentation by color prints. MAIN OUTCOME MEASURES: Frequency of detection and description of different lymph node vascularity patterns in signal-enhanced CDS.
RESULTS: Signal-enhanced CDS revealed additional information about vascularization of lymph node metastases, reactive lymph nodes, hematomas, and seromas, which was helpful for the differential diagnosis in 15 of 20 examinations. For lymph node metastases, signal enhancement facilitated the detection of accessory peripheral vessels in most investigations. Concerning reactive lymph nodes, hilar vessels in part with branching to the lymph node periphery could be identified only after application of the contrast enhancer in most patients. Quantitative variables could not be measured in all cases and did not help to differentiate between malignant and reactive lymph nodes.
CONCLUSIONS: Administration of a D-galactose-based signal enhancer for CDS in patients with cutaneous melanomas can help to differentiate malignant from reactive lymph nodes, hematomas, or seromas. However, these promising results require confirmation in a prospective multicenter study.

Entities:  

Mesh:

Year:  2002        PMID: 11939811     DOI: 10.1001/archderm.138.4.491

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  7 in total

Review 1.  Imaging the lymphatic system: possibilities and clinical applications.

Authors:  Olivier Clément; Alain Luciani
Journal:  Eur Radiol       Date:  2004-03-09       Impact factor: 5.315

Review 2.  New ultrasound techniques for lymph node evaluation.

Authors:  Xin-Wu Cui; Christian Jenssen; Adrian Saftoiu; Andre Ignee; Christoph F Dietrich
Journal:  World J Gastroenterol       Date:  2013-08-14       Impact factor: 5.742

3.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Authors:  Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01

Review 4.  Contrast-enhanced endobronchial ultrasound: Potential value of a new method.

Authors:  Christoph F Dietrich
Journal:  Endosc Ultrasound       Date:  2017 Jan-Feb       Impact factor: 5.628

Review 5.  Role of contrast-enhanced endoscopic ultrasound in lymph nodes.

Authors:  Michael Hocke; Andre Ignee; Christoph Dietrich
Journal:  Endosc Ultrasound       Date:  2017 Jan-Feb       Impact factor: 5.628

Review 6.  Contrast-enhanced ultrasound for the differential diagnosis between benign and metastatic superficial lymph nodes: a meta-analysis.

Authors:  Mei Mei; Ligang Ye; Juan Quan; Pintong Huang
Journal:  Cancer Manag Res       Date:  2018-10-26       Impact factor: 3.989

Review 7.  Contrast-enhanced endoscopic ultrasound.

Authors:  Christoph F Dietrich; M Sharma; M Hocke
Journal:  Endosc Ultrasound       Date:  2012-10       Impact factor: 5.628

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.